Frequency of anticancer drug use at the end of life : a scoping review

Endre Szigethy, Rosario Dorantes, Miguel Sugrañes, Meisser Madera, Ivan Solà, Gerard Urrútia, X. (Xavier) Bonfill

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

2 Cites (Scopus)

Resum

Anticancer drug use at the end of life places potential extra burdens on patients and the healthcare system. Previous articles show variability in methods and outcomes; thus, their results are not directly comparable. This scoping review describes the methods and extent of anticancer drug use at end of life. Systematic searches in Medline and Embase were conducted to identify articles reporting anticancer drug use at the end of life. We selected 341 eligible publications, identifying key study features including timing of research, disease status, treatment schedule, treatment type, and treatment characteristics. Among the subset of 69 articles of all cancer types published within the last 5 years, we examined the frequency of anticancer drug use across various end of life periods. This comprehensive description of publications on anticancer drug use at end of life underscores the importance of methodological factors when designing studies and comparing outcomes. The online version contains supplementary material available at 10.1007/s12094-023-03234-1.
Idioma originalAnglès
Pàgines (de-a)1-12
Nombre de pàgines12
RevistaClinical & Translational Oncology
DOIs
Estat de la publicacióPublicada - 2023

Fingerprint

Navegar pels temes de recerca de 'Frequency of anticancer drug use at the end of life : a scoping review'. Junts formen un fingerprint únic.

Com citar-ho